✦ LIBER ✦

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors

✍ Scribed by Jasleen Randhawa, Alen Ostojic, Radovan Vrhovac, Ehab Atallah, Srdan Verstovsek

Book ID: 119913633
Publisher: BioMed Central
Year: 2012
Tongue: English
Weight: 218 KB
Volume: 5
Category: Article
ISSN: 1756-8722
DOI: 10.1186/1756-8722-5-43

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Spleen deflation and beyond: The pros an

Spleen deflation and beyond: The pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms

✍ Alfonso Quintás-Cardama; Srdan Verstovsek 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 784 KB

AT9283, a potent inhibitor of the Aurora

AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders

✍ Mark A. Dawson; Jayne E. Curry; Kelly Barber; Philip A. Beer; Brent Graham; John 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 417 KB

Nonphosphate Inhibitors of IspE Protein,

Nonphosphate Inhibitors of IspE Protein, a Kinase in the Non-Mevalonate Pathway for Isoprenoid Biosynthesis and a Potential Target for Antimalarial Therapy

✍ Anna K. H. Hirsch; Susan Lauw; Philipp Gersbach; W. Bernd Schweizer; Felix Rohdi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 358 KB 👁 2 views

Inhibition of the Akt, cyclooxygenase-2,

Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: Potential therapeutic approaches for prostate cancer

✍ Hiroshi Miyamoto; Saleh Altuwaijri; Yi Cai; Edward M. Messing; Chawnshang Chang 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

## Abstract Prostate cancer cells are generally dependent on androgen stimulation mediated by the androgen receptor (AR) for growth and survival, and, therefore, hormonal manipulation, such as castration and/or the use of AR antagonists, results in a regression of the cancer. However, this treatmen

[RSC Drug Discovery] New Therapeutic Str

[RSC Drug Discovery] New Therapeutic Strategies for Type 2 Diabetes Volume 74 || Chapter 6. Recent Advances in PTP1B Inhibitor Development for the Treatment of Type 2 Diabetes and Obesity

✍ Jones, Rob M 📂 Article 📅 2012 🏛 Royal Society of Chemistry ⚖ 901 KB

NPM-ALK modulates the p53 tumour suppres

NPM-ALK modulates the p53 tumour suppressor pathway in a JNK and PI 3-Kinase dependent manner: MDM-2 is a potential therapeutic target for the treatment of ALK-expressing malignancies

✍ Y. Cui; A. Kerby; F.K.E. McDuff; S.D. Turner 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 90 KB